GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
Series GSE160195 Query DataSets for GSE160195
Status Public on Oct 28, 2020
Title Medication for acromegaly reduces expression of MUC16, MACC1 and GRHL2 in pituitary neuroendocrine tumour tissue
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Acromegaly is a disease mainly caused by pituitary neuroendocrine tumours (PitNETs) overproducing growth hormone. First-line medication for this condition is the use of somatostatin analogues (SSAs), that decrease tumour mass and induce antiproliferative effects on PitNET cells. Dopamine agonists (DAs) can also be used, if SSA treatment is not effective. This study aimed to determine differences in transcriptome signatures induced by SSA/DA therapy in PitNET tissue.
We selected tumour tissue from twelve patients with somatotrophinomas, with half of the patients receiving SSA/DA treatment before surgery, and the other half treatment naive. Transcriptome sequencing was then carried out to identify differentially expressed genes (DEGs) and their protein-protein interactions, using pathway analyses.
We found 34 upregulated and six downregulated DEGs in patients with SSA/DA treatment. Three tumour development promoting factors MUC16, MACC1 and GRHL2, were significantly downregulated in therapy administered PitNET tissue. Protein-protein interactions and pathway analyses revealed extracellular matrix involvement in the antiproliferative effects of this type of the drug treatment, with pronounced alterations in collagen regulation.
Here, we have demonstrated that somatotrophinomas can be distinguished based on their transcriptional profiles following SSA/DA therapy, and SSA/DA treatment does indeed cause changes in gene expression. Treatment with SSA/DA, significantly downregulated several factors involved in tumourigenesis, including MUC16, MACC1 and GRHL2. Genes that were upregulated, however, did not have a direct influence on antiproliferative function in the PitNET cells. These findings suggested that SSA/DA treatment acted in a tumour suppressive manner and furthermore, collagen related interactions and pathways were enriched, implicating extracellular matrix involvement in this anti-tumour effect of drug treatment.
Overall design PitNET RNA profiles in treated and untreated acromegaly patients
Please note that the 'PitNET06' and 'PitNET07' samples are outliers by their treatment.
Contributor(s) Saksis R, Silamikelis I, Laksa P, Megnis K, Peculis R, Balcere I, Konrade I, Steina L, Stukens J, Sokolovska J, Pirags V, Klovins J, Rovite V
Citation(s) 33680922
Submission date Oct 27, 2020
Last update date Mar 11, 2021
Contact name Raitis Peculis
Organization name Latvian Biomedical Research and Study Centre
Street address Ratsupites str 1 k-1
City Riga
ZIP/Postal code LV-1067
Country Latvia
Platforms (1)
GPL17303 Ion Torrent Proton (Homo sapiens)
Samples (12)
GSM4862222 PitNET01
GSM4862223 PitNET02
GSM4862224 PitNET03
BioProject PRJNA672302
SRA SRP288750

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE160195_read_counts_PitNET_DEG.txt.gz 722.2 Kb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap